{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Latest Alzheimer\u2019s Disease Diagnostic Criteria and Guidelines Show Importance of New Screening Tools to Detect Key Biomarkers - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"XYR2V4uN3p\"><a href=\"https:\/\/themedicalxchange.com\/en\/2012\/09\/04\/alzheimers-association-international-conference-20\/\">Latest Alzheimer\u2019s Disease Diagnostic Criteria and Guidelines Show Importance of New Screening Tools to Detect Key Biomarkers<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2012\/09\/04\/alzheimers-association-international-conference-20\/embed\/#?secret=XYR2V4uN3p\" width=\"600\" height=\"338\" title=\"&#8220;Latest Alzheimer\u2019s Disease Diagnostic Criteria and Guidelines Show Importance of New Screening Tools to Detect Key Biomarkers&#8221; &#8212; The Medical Xchange\" data-secret=\"XYR2V4uN3p\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2012\/09\/AAIC_2332_EN_Fig_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Vancouver \u2013 In 2011, The US National Institute on Aging (NIA) together with the Alzheimer\u2019s Association (AA) established new Alzheimer\u2019s disease (AD) spectrum diagnostic guidelines. The new classifications of the disease include a preclinical phase and illness in patients with mild cognitive impairment (MCI). They reflect a movement within the field of AD research to detect and treat the disease even before a person demonstrates outward symptoms. Consequently, the development of screening tools that will enable clinicians to detect key biomarkers for AD, specifically the presence of amyloid biomarkers and the Apolipoprotein E4 (APOE-e4) allele, as early indicators of cognitive decline, is yielding extremely promising results, and contributing to the validation of these new guidelines."}